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Abstract 
Purpose: The aim of this study was to demonstrate lipegfilgrastim superiority versus placebo in adults with non-
small cell lung cancer receiving myelosuppressive chemotherapy.
Methods: This phase III, double-blind study randomized chemotherapy-naive patients to receive cisplatin and 
etoposide with either lipegfilgrastim 6 mg or placebo. Because of the placebo control, patients at individual high 
risk for febrile neutropenia (FN; ≥20%) were excluded. Study drug was administered on day 4 (24 h after chemo-
therapy) of a 21-day cycle for ≤4 cycles. Primary efficacy measure was FN incidence in cycle 1. Secondary assessments 
included duration of severe neutropenia (DSN), absolute neutrophil count (ANC) profile, and adverse events (AEs).
Results: The study included 375 patients (lipegfilgrastim, n = 250; placebo, n = 125). Lipegfilgrastim superiority for 
FN incidence in cycle 1 was not achieved but incidence was lower (2.4%) versus placebo (5.6%). Cycle 1 mean DSN 
was significantly shorter for lipegfilgrastim (0.6 ± 1.1 days) versus placebo (2.3 ± 0.5 days; p < 0.0001). Incidence of 
severe neutropenia was significantly lower for lipegfilgrastim versus placebo overall and in each cycle (all, p < 0.0001). 
Mean ANC nadir was lowest in cycle 1 but significantly higher for lipegfilgrastim (1.60 ± 1.64) than placebo 
(0.67 ± 0.85; p < 0.0001). Mean time to ANC recovery was shorter with lipegfilgrastim in each cycle. Treatment-emer-
gent AEs were similar between treatment groups.
Conclusions: Lipegfilgrastim was not statistically superior to placebo for incidence of FN in cycle 1, but was more 
effective in reducing incidence of severe neutropenia, DSN, and time to ANC recovery, with an acceptable safety 
profile.
Controlled-trials.com identifier: ISRCTN55761467.
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Background
Neutropenia is a major dose-limiting toxicity in many 
myelosuppressive chemotherapy regimens (Holmes et al. 
2002; Crawford et  al. 2013). A patient’s risk of develop-
ing neutropenia or febrile neutropenia (FN) depends on 
several factors, including the type of cancer, chemother-
apy regimen (standard-dose, dose-dense, or high-dose 
therapy), and patient-related and disease-related factors, 
such as age and comorbidities (Crawford et al. 2013).
Recombinant granulocyte colony-stimulating factors 
(G-CSFs) promote the proliferation and differentiation 
of neutrophils, alleviating the severity of chemotherapy-
induced neutropenia and FN (Cooper et al. 2011). These 
agents are well established as primary prophylaxis for FN 
Open Access
*Correspondence:  cvolovat@yahoo.com 
1 Centrul de Oncologie Medicala, Vasile Conta 2 Str, 700106 Iasi, Romania
Full list of author information is available at the end of the article
Page 2 of 11Volovat et al. SpringerPlus  (2015) 4:316 
and are recommended in European and US guidelines 
for chemotherapy patients at high (≥20%) risk of FN 
(Crawford et al. 2010, 2013; Smith et al. 2006; Aapro et al. 
2011). Filgrastim, the first recombinant human G-CSF, 
requires daily subcutaneous (SC) injections (Neupogen 
[package insert] 2013). With the attachment of polyeth-
ylene glycol (PEG) to the G-CSF molecule, the half-life 
of pegfilgrastim was extended compared with filgrastim, 
allowing once-per-chemotherapy cycle administration 
(Neulasta [package insert] 2012). Lipegfilgrastim is a gly-
coPEGylated, once-per-cycle recombinant human G-CSF 
expressed in Escherichia coli. It is approved by the Euro-
pean Medicines Agency for reducing the duration of neu-
tropenia and the incidence of FN in adults treated with 
cytotoxic chemotherapy for malignancy (with the excep-
tion of chronic myeloid leukemia and myelodysplastic 
syndromes) (Lonquex 2013).
A recent phase III trial (controlled-trials.com identifier 
ISRCTN56891934) demonstrated the clinical efficacy of 
lipegfilgrastim to be noninferior to pegfilgrastim in reduc-
ing neutropenia in breast cancer patients receiving mye-
losuppressive chemotherapy (Bondarenko et  al. 2013). 
This trial was conducted to demonstrate superiority of 
once-per-cycle lipegfilgrastim versus placebo in patients 
with stage IIIb/IV non-small cell lung cancer (NSCLC) 
receiving up to four cycles of cisplatin and etoposide 
chemotherapy. Evaluations of efficacy, tolerability, and 
pharmacokinetic properties were secondary assessments.
Results
The study was conducted between May 2010 and April 
2011 at 72 centers in eight countries. In total, 427 
patients were screened and 376 were randomized (Bela-
rus, n = 34; Bosnia-Herzegovina, n = 2; Bulgaria, n = 16; 
Poland, n = 4; Romania, n = 25; Russia, n = 160; Serbia, 
n  =  20; Ukraine, n  =  115). One patient in the lipegfil-
grastim group who was randomized in error and received 
no chemotherapy or study medication was excluded from 
the efficacy and safety analyses. Thus, 250 patients in the 
lipegfilgrastim group and 125 in the placebo group were 
included in the intent-to-treat population (Figure 1). Of 
these, 169 (67.6%) patients in the lipegfilgrastim and 81 
(64.8%) in the placebo group completed treatment. Two 
patients in the lipegfilgrastim group who died after ran-
domization but did not receive study medication were 
included in the efficacy but not safety analyses.
Patients
Baseline demographics and clinical characteristics 
were similar between treatment groups (Table  1). Most 
patients were men, had stage IV NSCLC, an East-
ern Cooperative Oncology Group Performance Status 
(ECOG PS) of 1, and were receiving chemotherapy for 
metastatic disease. The mean age was similar in both 
groups and was somewhat younger than is typically seen 
for patients with lung cancer. However, this was expected 
as one of the risk factors that would have contributed to 
the exclusion of patients at individual high risk for FN 
was age >65 years, leading to a relatively low percentage 
of patients aged >65 years (23.5%) being enrolled.
Most patients in both treatment groups received their 
planned chemotherapy dose in each cycle; ≤3.3% of 
patients receiving placebo and ≤2.3% of those receiving 
lipegfilgrastim had a dose reduction or omission. The 
total number of administered doses for both cisplatin and 
etoposide was similar between treatment groups (data 
not shown). The proportion of patients with chemother-
apy dose delays was significantly lower in patients treated 
with lipegfilgrastim than in those receiving placebo (cycle 
2, 28.5 vs. 65.1%; cycle 3, 42.1 vs. 66.3%; and cycle 4, 40.4 
vs. 75.3%, respectively; all p ≤ 0.0001). The mean duration 
of chemotherapy delay across all cycles also was shorter 
for patients receiving lipegfilgrastim (6.4 ± 7.6 days) ver-
sus those receiving placebo (12.8 ± 10.2 days).
Efficacy
The primary efficacy measure, incidence of FN in cycle 
1, was lower in the lipegfilgrastim group compared with 
the placebo group (Table  2), but the difference was not 
significant. Thus, the study failed to achieve its primary 
objective of demonstrating superiority of lipegfilgrastim 
versus placebo in these patients.
Seven investigator-assessed cases of FN were observed 
during cycles 2, 3, and 4 (Table 2), but no significant dif-
ferences in the incidence of FN between treatment groups 
were observed (p > 0.05). None of the patients switched to 
open-label lipegfilgrastim experienced FN during chemo-
therapy cycles 2, 3, and 4. Patients receiving lipegfilgrastim 
experienced a significantly shorter duration of severe neu-
tropenia (DSN) in cycle 1 compared with patients receiv-
ing placebo (p  <  0.0001; Table  3). Similarly, the DSN in 
cycles 2, 3, and 4 was consistently and significantly shorter 
in the lipegfilgrastim group compared with the placebo 
group (p  <  0.0001, all cycles). The incidence of severe 
neutropenia was significantly lower in the lipegfilgrastim 
group versus the placebo group overall (p  <  0.0001) and 
in each cycle (p  <  0.0001, each cycle; Table  4). Notably, 
in cycles 2, 3, and 4, approximately 80% of patients in the 
lipegfilgrastim group experienced no severe neutropenia 
compared with approximately 40% in the placebo group.
Patients treated with lipegfilgrastim experienced 
a shorter mean duration of very severe neutropenia 
[absolute neutrophil count (ANC) <0.1 ×  109/L] versus 
patients receiving placebo in cycle 1: 0.3 ± 0.9 days ver-
sus 0.2 ± 0.6 days for lipegfilgrastim and placebo, respec-
tively. The mean duration of very severe neutropenia 
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was also shorter for patients in the lipegfilgrastim group 
compared with the placebo group in cycles 2, 3, and 4. 
Patients receiving lipegfilgrastim had a significantly 
lower incidence of very severe neutropenia over all 
cycles versus those receiving placebo (p  =  0.017). Dif-
ferences between groups also were significant in cycles 
2 (p = 0.031) and 4 (p = 0.007), with the lipegfilgrastim 
group having a lower incidence (Table 4).
The time course of median ANC during cycle 1 is 
shown in Figure  2. The mean depth of the ANC nadir 
in both treatment groups was lowest in cycle 1, but was 
significantly higher in patients treated with lipegfil-
grastim (1.6 ± 1.6 × 109/L) versus patients receiving pla-
cebo (0.7 ± 0.9 × 109/L); p < 0.0001). In cycles 2, 3, and 4, 
the mean ANC nadir was greater than 2.5 × 109/L for the 
lipegfilgrastim group, but remained below 1.0 × 109/L for 
the placebo group (mean 2.8 vs. 0.8, 2.8 vs. 0.8, and 2.6 vs. 
0.7 × 109/L, respectively; p < 0.0001 in each case).
The mean time to ANC nadir was consistently shorter 
in the lipegfilgrastim group compared with the placebo 
group in each cycle (cycle 1: 8.2 vs. 13.7; cycle 2: 9.6 vs. 
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Figure 1 Patient disposition from randomization to study completion. *One patient randomized in error received no chemotherapy and no study 
medication and was excluded from all statistical analyses and populations. †Two patients who received chemotherapy but died after randomiza-
tion, before study medication was administered, were included in the efficacy population but not in the safety population. ‡Adverse events listed 
as the primary reason for study discontinuation include placebo patients: two patients each with febrile neutropenia, cerebral infarction, and 
pneumonia; one patient each with back pain, general physical health deterioration, arterial thrombosis in a limb, pain in the extremities, inadequate 
control of diabetes mellitus, tumor lysis syndrome, and neutropenia; and one patient with anemia, thrombocytopenia, and neutropenia; lipegfil-
grastim patients: two patients with anemia; one patient each with wound necrosis, syphilis, atrial fibrillation, pyothorax, fatigue, increased aspartate 
aminotransferase, gastric hemorrhage, dementia, pulmonary embolism, asthenia, and hemoptysis. §Includes patients lost to follow-up (n = 2), treat-
ment failure (n = 3), and other (n = 5). AE adverse event, ITT intent to treat, PD progression of underlying disease.
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addition, the mean time to ANC recovery from ANC 
nadir was significantly shorter in the lipegfilgrastim ver-
sus placebo group in each cycle (cycle 1: 1.1 vs. 2.7; cycle 
2: 0.6 vs. 2.6; cycle 3: 0.8 vs. 2.3; cycle 4: 0.7 vs. 2.6 days; 
p  <  0.0001 between groups in each cycle). Patients 
treated with lipegfilgrastim also experienced a signifi-
cantly shorter mean time to ANC recovery after chem-
otherapy in each chemotherapy cycle compared with 
patients receiving placebo (cycle 1: 6.8 vs. 13.0; cycle 2: 
5.6 vs. 13.8; cycle 3: 6.0 vs. 13.7; cycle 4: 5.4 vs. 14.0 days, 
respectively; p < 0.0001 between groups in each cycle).
Safety
During the double-blind phase, 171 (69.0%) patients in 
the lipegfilgrastim group and 81 (64.8%) in the placebo 
group received four doses of study medication. The mean 
total amount of study medication administered was 
19.9 ±  6.7  mg and 19.3 ±  7.0  mg in the lipegfilgrastim 
and placebo groups, respectively.
Adverse events (AEs) were similar between treatment 
groups. The most common AEs (total incidence of ≥10% 
in either treatment group) in the lipegfilgrastim and pla-
cebo groups were alopecia (40.7 and 33.6%), anemia (25.4 
and 24.0%), nausea (23.8 and 21.6%), neutropenia (20.6 
and 35.2%), thrombocytopenia (12.9 and 8.0%), asthenia 
(11.3 and 18.4%), vomiting (11.3 and 12.0%), and leu-
kopenia (6.5 and 11.2%), respectively (Table  5). In total, 
57 (23.0%) patients in the lipegfilgrastim group and 33 
(26.4%) patients in the placebo group experienced an AE 
that lead to discontinuation from the study.
Bone-pain-related symptoms (defined as arthralgia, 
back pain, bone pain, myalgia, noncardiac chest pain, and 
pain in extremity) were reported in 21 (8.5%) patients 
treated with lipegfilgrastim and 8 (6.4%) patients receiv-
ing placebo. These events were generally mild or moder-
ate in severity and led to study discontinuation in only 
two patients (both receiving placebo).
Serious AEs in the lipegfilgrastim and placebo groups 
included anemia (3.2 and 1.6%), NSCLC (3.2 and 0.8%), 
disease progression (2.4 and 0%), FN (2.0 and 4.0%), neu-
tropenia (1.6 and 0.8%), pulmonary embolism (1.2 and 
1.6%), cardio-respiratory arrest (1.2% and 0), thrombocy-
topenia (1.2% and 0), pneumonia (0.8 and 2.4%), pulmo-
nary hemorrhage (0.8% and 0), renal failure (0.8% and 0), 
and sudden death (0.8% and 0), respectively.
A total of 31 (12.5%) patients treated with lipegfil-
grastim and nine (7.2%) patients receiving placebo died 
during the course of the study or up to 30 days after the 
last study drug injection. General disorders and admin-
istration site conditions accounted for eight deaths in 
the lipegfilgrastim group and two in the placebo group; 
benign, malignant, and unspecified neoplasms for eight 
in the lipegfilgrastim group and two in the placebo 
group; respiratory, thoracic, and mediastinal disorders 
for five in the lipegfilgrastim group and three in the 
placebo group; cardiac disorders for four in the lipeg-
filgrastim group and one in the placebo group; vascular 
disorders for two in the lipegfilgrastim group; renal and 
urinary disorders for two in the lipegfilgrastim group; 
nervous system disorders for one in the lipegfilgrastim 
group and one in the placebo group; and metabolism 
and nutrition disorders for one in the lipegfilgrastim 
group.
Changes over time in laboratory assessments were 
consistent with the underlying disease and with the 
Table 1 Patient demographics and baseline characteristics 
(intent-to-treat population)
ECOG PS Eastern Cooperative Oncology Group Performance Status, NSCLC non-
small cell lung cancer, SC subcutaneously, SD standard deviation.





 Mean ± SD 58.7 ± 8.5 58.2 ± 8.5
 ≤64, n (%) 94 (75.2) 193 (77.2)
 65–74, n (%) 29 (23.2) 54 (21.6)
 ≥75, n (%) 2 (1.6) 3 (1.2)
Weight, kg
 Mean ± SD 70.4 ± 13.4 69.0 ± 12.9
 ≤60, n (%) 34 (27.2) 70 (28.0)
 >60 to ≤75, n (%) 53 (42.4) 106 (42.4)
 >75, n (%) 38 (30.4) 74 (29.6)
Sex, n (%)
 Female 20 (16.0) 30 (12.0)
 Male 105 (84.0) 220 (88.0)
Region, n (%)
 Russia 54 (43.2) 106 (42.4)
 Ukraine 38 (30.4) 77 (30.8)
 Rest of Europe 33 (26.4) 67 (26.8)
NSCLC stage at enrolment, n (%)
 Stage IIIB 49 (39.2) 97 (38.8)
 Stage IV 76 (60.8) 152 (60.8)
 Unknown 0 (0) 1 (0.4)
Time since diagnosis, months
 Mean ± SD 3.4 ± 9.1 2.4 ± 6.2
 Median (range) 1.0 (0–58.0) 1.0 (0–52.0)
ECOG PS, n (%)
 0 19 (15.2) 28 (11.2)
 1 96 (76.8) 194 (77.6)
 2 10 (8.0) 28 (11.2)
Reason for chemotherapy, n (%)
 Adjuvant therapy 21 (16.8) 35 (14.0)
 Treatment for metastatic 
disease
104 (83.2) 215 (86.0)
Lung cancer surgery
 No 98 (78.4) 215 (86.0)
 Yes 27 (21.6) 35 (14.0)
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chemotherapy treatment received and, in the lipegfil-
grastim group, with G-CSF therapy.
Discussion
In this study, patients with NSCLC and a low individ-
ual risk of FN who received lipegfilgrastim had a lower 
incidence of FN during cycle 1 (2.4%) compared with 
patients receiving placebo (5.6%). The incidence of FN 
was in line with previously published results for peg-
filgrastim (Vogel et  al. 2005). Because the difference 
between treatment groups was not statistically sig-
nificant, the study did not achieve its primary efficacy 
measure of demonstrating the superiority of lipegfil-
grastim versus placebo. Nevertheless, the reduction in 
the incidence of FN in cycle 1 of >50% in the lipegfil-
grastim group versus the placebo group is clinically 
important, particularly when considering the potential 
serious effects of FN on the overall health of patients. 
The actual incidence of FN was lower than anticipated 
for the placebo group and higher than anticipated for 
the lipegfilgrastim group, affecting the statistical power 
of the study. The use of prophylactic G-CSFs is not rec-
ommended by treatment guidelines unless a patient’s 
risk for developing FN is high (≥20%); however, the 
current study used chemotherapy with a reported inci-
dence of FN <20% and excluded patients with an indi-
vidual high risk of developing FN (≥20% risk). Thus, 
the use of prophylactic G-CSF therapy in this study was 
experimental in nature and provides additional evidence 
for the recommendation that prophylactic G-CSFs 
should not be used in patients with a risk of FN <20% 
(Crawford et  al. 2010, 2013; Smith et  al. 2006; Aapro 
et  al. 2011). The use of cisplatin and etoposide, along 
with the strict definition of FN, may have contributed to 
the overall rate of FN being lower than the rate reported 
for patients receiving placebo in previously published 
lung cancer studies using the same chemotherapy regi-
men (Bonomi et al. 2000; Cardenal et al. 1999; Eckardt 
et  al. 2006; Hanna et  al. 2006). In particular, exclud-
ing patients thought to be at high risk for FN led to a 
relatively low percentage of patients aged ≥65  years 
(24.8%). In a similar study of patients with NSCLC 
receiving myelosuppressive chemotherapy and adjuvant 
filgrastim therapy or placebo, 41.1% of all patients were 
aged ≥65  years. Of these patients, 71 and 43% experi-
enced FN in the placebo and filgrastim groups, respec-
tively (Crawford et al. 2005).
Table 2 Febrile neutropenia in cycles 1, 2, 3, and 4 (intent-to-treat population)
CI confidence interval, FN febrile neutropenia, NE not evaluable, OR odds ratio, SC subcutaneously.
* P values based on a null hypothesis of odds ratio = 1.
Cycle Placebo Lipegfilgrastim 6 mg SC Lipegfilgrastim 6 mg SC vs. placebo
N FN % N FN % OR 95% CI P value*
1 125 7 5.6 250 6 2.4 0.390 0.121–1.260 0.1151
2 105 0 0 214 1 0.5 NE NE 0.9551
3 92 1 1.1 188 1 0.5 0.642 0.234–1.762 0.3883
4 81 2 2.5 171 2 1.2 0.421 0.119–1.489 0.1787
Table 3 Duration of  severe neutropenia in  cycles 1, 2, 3, 
and 4 (ITT population)
Includes patients from the ITT population who were withdrawn from the study.
CI confidence interval, ITT intent to treat, LSM least squares mean, SC subcutane-
ously, SD standard deviation.
*Least squares mean, 95% CI, and P value are for Poisson regression analysis 
lipegfilgrastim–placebo.
Cycle Duration of severe 
neutropenia (days)
Placebo Lipegfilgrastim 6 mg SC
1 N 125 250
Mean ± SD 2.3 ± 2.5 0.6 ± 1.1
Median (range) 2.0 (0–11.0) 0 (0–5.0)
LSM* −1.661
95% CI* −2.089 to −1.232
P value* <0.0001
2 N 122 244
Mean ± SD 2.2 ± 2.6 0.3 ± 0.7
Median (range) 1.0 (0–11.0) 0 (0–4.0)
LSM* −1.915
95% CI* −2.317 to −1.512
P value* <0.0001
3 N 122 245
Mean ± SD 2.0 ± 2.4 0.4 ± 0.9
Median (range) 1.0 (0–11.0) 0 (0–5.0)
LSM* −1.640
95% CI* −2.053 to −1.227
P value* <0.0001
4 N 123 246
Mean ± SD 2.3 ± 2.5 0.5 ± 1.1
Median (range) 1.0 (0–11.0) 0 (0–0.8)
LSM* −1.844
95% CI* −2.281 to −1.407
P value* <0.0001
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The study design and statistical assumptions of this 
phase III trial may have contributed to not achieving the 
primary measure of demonstrating superiority to pla-
cebo in the incidence of FN in cycle 1. The existence of 
effective G-CSF supportive care and the uniformity of 
treatment guidelines for the use of G-CSFs in patients 
at risk for developing chemotherapy-induced neutrope-
nia mean that a placebo-controlled trial in this setting is 
now uncommon. In addition, the strict definition of FN 
used in this study may have excluded patients who oth-
erwise may have been reported as having FN. Moreover, 
the incidence of FN in cycle 1 was used as the primary 
measure, whereas G-CSF studies often use DSN in cycle 
1 as the primary measure.
At the time the study was conducted, cisplatin and 
etoposide chemotherapy at the doses used was recom-
mended for patients with stage IIIb/IV NSCLC (Belani 
et  al. 2005). The reported incidence of FN for this regi-
men ranged from 8 to 12% in a population with an aver-
age risk of FN (Bonomi et al. 2000; Cardenal et al. 1999; 
Eckardt et  al. 2006; Hanna et  al. 2006), permitting the 
placebo-controlled study design. After the completion of 
this study, a systematic review and meta-analysis of the 
use of G-CSFs for FN prophylaxis following chemother-
apy was published (Cooper et al. 2011). Although a broad 
range of studies was included, no study of patients with 
NSCLC receiving cisplatin and etoposide chemotherapy 
was included. The meta-analysis reported a risk ratio for 
Table 4 Incidence of severe and very severe neutropenia in cycles 1, 2, 3, and 4 (ITT population)
Based on data actually collected.
ANC absolute neutrophil count, CI confidence interval, ITT intent to treat, NS not significant, SC subcutaneously.
*P values based on a null hypothesis of odds ratio = 1.
Cycle Placebo Lipegfilgrastim 6 mg SC Lipegfilgrastim 6 mg SC vs. placebo
N n % N n % Odds ratio 95% CI P value*
Severe neutropenia (grade 4, ANC <0.5 × 109/L)
 1 125 74 59.2 249 80 32.1 0.325 0.206–0.512 <0.0001
 2 105 55 52.4 215 36 16.7 0.156 0.086–0.282 <0.0001
 3 92 47 51.1 188 26 13.8 0.115 0.057–0.229 <0.0001
 4 81 45 55.6 169 25 14.8 0.121 0.062–0.238 <0.0001
 All 125 100 80.0 249 103 41.4 0.176 0.105–0.294 <0.0001
Very severe neutropenia (ANC <0.1 × 109/L)
 1 125 18 14.4 249 27 10.8 0.700 0.365–1.342 NS
 2 105 10 9.5 215 8 3.7 0.298 0.099–0.895 0.031
 3 92 9 9.8 188 9 4.8 0.421 0.156–1.138 NS
 4 81 11 13.6 169 8 4.7 0.260 0.098–0.687 0.007
 All 125 33 26.4 249 40 16.1 0.516 0.300–0.888 0.017
Figure 2 Time course of measured median absolute neutrophil count in cycle 1 (intent-to-treat population). ANC absolute neutrophil count.
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FN of 0.30 [95% confidence interval (CI), 0.14–0.65] for 
pegfilgrastim and 0.57 (95% CI, 0.48–0.69) for filgrastim. 
In the current study, the odds ratio (OR) for FN in cycle 
1 of 0.39 (95% CI, 0.121–1.260) for the comparison of 
lipegfilgrastim with placebo is in line with these results.
Secondary objectives of this study included the dura-
tion and incidence of severe neutropenia, and ANC pro-
file (including depth of and time to ANC nadir, and time 
to ANC recovery). For most of these secondary meas-
ures, treatment with lipegfilgrastim was superior to pla-
cebo. In each of the four chemotherapy cycles, DSN was 
significantly shorter in the lipegfilgrastim group versus 
the placebo group (p  <  0.0001), and in cycles 2, 3, and 
4; approximately 80% of the lipegfilgrastim group expe-
rienced no severe neutropenia compared with approxi-
mately 40% of the placebo group. The incidence of severe 
neutropenia also was significantly lower in the lipegfil-
grastim group versus the placebo group (p  <  0.0001). 
A commonly used primary measure in studies with 
G-CSFs, DSN in cycle 1 was used as a primary measure 
in a recently published study that found lipegfilgrastim 
to be noninferior to pegfilgrastim in patients with breast 
cancer (Bondarenko et al. 2013). In the current study, the 
depth of ANC nadir was significantly lower in patients 
treated with lipegfilgrastim versus patients receiving pla-
cebo (p  <  0.0001), and time to ANC nadir was shorter 
with lipegfilgrastim treatment. Time to ANC recovery 
also was shorter in the lipegfilgrastim group compared 
with the placebo group. Furthermore, significantly fewer 
patients receiving lipegfilgrastim had chemotherapy dose 
delays compared with those receiving placebo. These 
results add further support to data indicating the clinical 
benefits of lipegfilgrastim (Bondarenko et al. 2013; Buch-
ner et al. 2011).
The high incidence of AEs was anticipated in this 
population of patients with stage IIIb/IV NSCLC receiv-
ing chemotherapy, and AEs were consistent with the 
underlying disease and chemotherapy regimen adminis-
tered. In addition to neutropenia, the most common AEs 
(≥10% in either group) were alopecia, anemia, nausea, 
thrombocytopenia, asthenia, vomiting, and leukopenia—
all known to be associated with the chemotherapy agents 
used in this study. The incidence of study medication-
related AEs was relatively low. Bone-pain-related symp-
toms, known AEs associated with G-CSF therapy, were 
generally mild or moderate in severity. The incidence of 
mortality in this study was low, considering that the study 
population had advanced-stage disease. Most deaths 
were related to NSCLC or to other underlying conditions 
and were not considered to be related to lipegfilgrastim 
treatment. Deaths occurred early in and did not increase 
during the study; no difference in mortality was observed 
at the end of the 12-month follow-up, suggesting that the 
difference in mortality between the lipegfilgrastim and 
placebo groups at the end of the study was likely a chance 
effect.
The incidence of FN in patients with NSCLC receiv-
ing lipegfilgrastim or placebo in this study is similar to 
those reported in two placebo-controlled studies of peg-
filgrastim in patients with advanced or metastatic colo-
rectal cancer receiving chemotherapy regimens reported 
to have a low risk of FN (allowing the use of a placebo 
group). Again, the use of prophylactic G-CSF therapy in 
this setting is experimental, as the main chemotherapy 
regimens administered (oxaliplatin, fluorouracil, and 
leucovorin [FOLFOX4] or irinotecan, fluorouracil [infu-
sion], and leucovorin [FOLFIRI]) have been reported to 
have a 6 and 9% incidence of FN, respectively, in patients 
with advanced colorectal cancer (Smith et  al. 2006). 
In the large phase III trial (N = 845), grade 3/4 FN was 
reported in 2.4% of patients receiving pegfilgrastim and 
in 5.7% of patients receiving placebo after four cycles 
of chemotherapy (p =  0.014) (Pinter et al. 2013). In the 
phase II study (n = 252), grade 3/4 FN was reported in 
2% of pegfilgrastim recipients and 8% of placebo recipi-
ents after four cycles of chemotherapy (p = 0.04) (Hecht 
et al. 2010).
Table 5 Most frequent TEAEs (≥5% of  patients) in  either 
treatment group across all cycles (safety population)
TEAEs include all AEs except those specifically rated by investigators as unre-
lated to study drug. Multiple mentions per patient are possible. TEAEs with 
onset after the start of prophylactic open-label lipegfilgrastim treatment are 
excluded.
AE adverse event, NSCLC non-small cell lung cancer, SC subcutaneously, TEAEs 
treatment-emergent adverse events.
AE by preferred term Placebo (N = 125) Lipegfilgrastim 
6 mg SC 
(N = 248)
n % n %
Alopecia 42 33.6 101 40.7
Anemia 30 24.0 63 25.4
Nausea 27 21.6 59 23.8
Neutropenia 44 35.2 51 20.6
Thrombocytopenia 10 8.0 32 12.9
Asthenia 23 18.4 28 11.3
Vomiting 15 12.0 28 11.3
Decreased appetite 12 9.6 23 9.3
Hypokalemia 3 2.4 20 8.1
Leukopenia 14 11.2 16 6.5
Fatigue 6 4.8 16 6.5
Disease progression 5 4.0 16 6.5
NSCLC 4 3.2 16 6.5
Chest pain 8 6.4 14 5.6
Febrile neutropenia 10 8.0 11 4.4
Dyspnea 9 7.2 11 4.4
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In this study in patients with stage IIIb/IV NSCLC, 
treatment with lipegfilgrastim did not demonstrate 
superiority to placebo in terms of the incidence of FN 
in cycle 1. Use of a G-CSF in this setting was investiga-
tional in that it was administered to patients contrary 
to current treatment guidelines (Crawford et  al. 2010, 
2013; Smith et al. 2006; Aapro et al. 2011), yet treatment 
with lipegfilgrastim was consistently more effective 
than placebo in reducing the duration and incidence of 
severe neutropenia and time to ANC recovery, with an 
acceptable safety and tolerability profile in this patient 
population.
Methods
This phase III, multinational, multicenter, double-blind, 
randomized, placebo-controlled study (controlled-
trials.com identifier ISRCTN55761467) was designed 
to demonstrate superiority of a fixed 6-mg dose of 
lipegfilgrastim (XM22, Lonquex; Teva Pharmaceuti-
cals Ltd, Petach Tikva, Israel) versus placebo in patients 
with NSCLC. The study was conducted in eight Euro-
pean countries (Belarus, Bosnia-Herzegovina, Bulgaria, 
Poland, Romania, Russia, Serbia, Ukraine) and included 
four phases: screening and randomization, double-blind 
treatment (chemotherapy cycles 1–4), end-of-study (or 
withdrawal) visit, and antibody follow-up. The study 
design followed the European Medicines Agency’s guide-
lines for a confirmatory study (EMEA 2007). Everyone 
involved in the conduct of the study was blinded to study 
medications.
Patients
Eligible patients were men and women aged ≥18  years 
of any ethnic origin with a diagnosis of stage IIIb/IV 
NSCLC, documented histologically or cytologically, 
and a life expectancy of at least 4  months. Patients had 
to be chemotherapy naive, eligible to receive four cycles 
of cisplatin and etoposide as myelosuppressive chemo-
therapy (i.e., baseline ANC ≥1.5  ×  109/L and platelets 
≥100  ×  109/L), have an ECOG PS ≤2, and have ade-
quate hepatic, cardiac, and renal function. Women of 
childbearing potential had to use an effective method of 
contraception.
Because this was a placebo-controlled study, patients 
with an individual high risk of developing FN (i.e., 
≥20%) with regard to the cisplatin and etoposide chem-
otherapy were excluded from the study. Potential indi-
vidual high risk factors were patient age >65 years, low 
ECOG PS, poor nutritional status, and liver, kidney, or 
cardiovascular disease. Risk factors were considered 
together to determine a patient’s risk of developing 
FN, and therefore having only one risk factor did not 
automatically result in exclusion from the study. Other 
exclusion criteria included previous exposure to any 
G-CSF within 6  months before randomization, treat-
ment with systemically active antibiotics within 72  h 
before chemotherapy, chronic use of oral corticoster-
oids, prior radiation therapy within 4 weeks of randomi-
zation, prior bone marrow or stem cell transplantation, 
or concomitant malignancy (other than in  situ mela-
noma, skin cancer, or cervical carcinoma) within the 
preceding 5  years. Women who were pregnant or 
breastfeeding were excluded.
Study design and treatment
All patients received chemotherapy with cisplatin 
and etoposide and were randomized (2:1) to receive 
lipegfilgrastim or placebo. Randomization was per-
formed by Biostatistics Merckle GmbH through an 
interactive voice response system, using a block size 
of 2 and stratified by country. Patients received up to 
four 21-day chemotherapy cycles. On day 1 of each 
cycle, patients received cisplatin 80  mg/m2 intrave-
nously (IV), with etoposide 120  mg/m2 IV adminis-
tered on days 1, 2, and 3. Patients had to have an ANC 
≥1.5 ×  109/L and platelet count of ≥100 ×  109/L to 
begin the next full-dose cycle. A dose delay of up to 
2  weeks was acceptable. Absolute neutrophil counts 
were determined at local or regional laboratories 
rather than a central laboratory, for logistical reasons; 
all other laboratory measures were determined by two 
central laboratories. In addition, the patient’s overall 
condition had to allow further chemotherapy treat-
ment as determined by the treating investigator. Gen-
erally, any chemotherapy-related toxicity had to have 
resolved to at least grade 1 toxicity prior to continua-
tion of chemotherapy.
Patients received one dose of lipegfilgrastim 6  mg 
or placebo SC on day 4 of each chemotherapy cycle, 
approximately 24 h after the last chemotherapy infusion 
and after blood sampling to determine ANC and body 
temperature. The lipegfilgrastim 6-mg dose was chosen 
based on findings from a phase II dose-finding study in 
breast cancer patients that demonstrated neutrophil sup-
port that was at least equivalent to the standard 6.0-mg 
fixed dose of pegfilgrastim. Patients who developed FN 
in any cycle were not discontinued except by investiga-
tor decision; instead, they received open-label prophylac-
tic treatment with lipegfilgrastim in subsequent cycles, 
regardless of treatment group.
Efficacy assessments
The primary efficacy measure was the incidence of FN in 
cycle 1. Febrile neutropenia was defined as an oral body 
temperature >38.5°C for at least 1  h (two consecutive 
same-day measurements, ≥60  min apart) with severe 
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neutropenia (ANC <0.5 × 109/L) on the day before, same 
day, or day after the elevated temperature readings; neu-
tropenic sepsis (sepsis with ANC <0.5 × 109/L); or seri-
ous or life-threatening neutropenic infection (infection 
with ANC <0.5 × 109/L).
Secondary efficacy measures included the incidence of 
FN in cycles 2, 3, and 4 and across all cycles; incidence 
and DSN (defined as grade 4 neutropenia with ANC 
<0.5  ×  109/L); incidence and duration of very severe 
neutropenia (ANC <0.1  ×  109/L); depth of ANC nadir 
(lowest ANC in each cycle); time to ANC nadir (defined 
as time from chemotherapy administration until occur-
rence of ANC nadir); time to ANC recovery (defined 
as time from chemotherapy administration until ANC 
increased to ≥2.0 × 109/L after nadir); and time to ANC 
recovery from ANC nadir (defined as the difference in 
days between day of ANC nadir to first day with ANC 
≥1.5 × 109/L).
Blood samples to determine ANC were obtained 
daily until day 15, or longer, of each cycle, until ANC 
≥2.0 × 109/L was reached. A blood sample was taken on 
day 4 of each cycle, before administration of study medi-
cation. Body temperature was measured orally at least 
twice daily (morning and evening) until day 15, or longer, 
of each cycle, until ANC ≥2.0 × 109/L was reached.
Other secondary efficacy measures, including hospital-
izations, use of IV antibiotics, delivered versus scheduled 
chemotherapy, chemotherapy dose modifications (reduc-
tions, omissions, delays), quality of life, and the incidence 
of patients requiring prophylactic open-label treatment, 
as well as pharmacokinetic properties were assessed but 
are not reported here.
Safety assessments
Safety was assessed using reported treatment-emergent 
AEs data, including intercurrent illnesses and clinically 
abnormal laboratory values; AEs were recorded until 
3  weeks after the last injection of study medication. 
Adverse events were summarized by seriousness, sever-
ity, and investigator-assessed relationship to study medi-
cation. A serious AE was one that was life-threatening 
or resulted in death, required hospitalization or prolon-
gation of hospitalization, or resulted in a persistent or 
significant disability or incapacity that required medical 
or surgical intervention. Investigators assessed AEs as 
probably, possibly, unlikely, or not related to the study 
medication or chemotherapy regimen, or as not classifi-
able. For laboratory values, all AEs of grade 3 and higher 
were documented. The AEs were assessed on days 1 and 
7 of each chemotherapy cycle. Safety samples (hematol-
ogy and clinical chemistry) were taken on day 15. Other 
safety assessments, including physical examination and 
vital signs, were performed within 24  h before chemo-
therapy administration on day 1 and on days 7 and 15 of 
each chemotherapy cycle.
Statistical analysis
The planned sample size was 375 patients from approxi-
mately 90 centers in nine countries, based on the assump-
tion that the incidence of FN would be in the range of 7% 
to 10% in the placebo group and, at most, 1% in the lipeg-
filgrastim group. For a statistical test with a two-sided 
significance level α of 5%, a required power of at least 
80%, and a sampling rate of 2:1 (lipegfilgrastim:placebo), 
sample size requirements were 250 patients in the lipeg-
filgrastim group and 125 patients in the placebo group. 
As the actual incidence of FN in the placebo group was 
expected to be closer to 10%, a power of at least 90% was 
expected.
For the primary efficacy measure (incidence of FN in 
cycle 1), a 95% CI for the OR (placebo/lipegfilgrastim) 
was calculated to assess the relative efficacy of lipegfil-
grastim versus placebo. For secondary efficacy meas-
ures, no adjustment for Type I error was applied, so all 
secondary analyses should be interpreted as exploratory. 
When applicable, for secondary efficacy measures for 
which regression analyses were planned, statistical mod-
els with the same explanatory variables as in the analysis 
of the primary measures were estimated. Demographic 
and baseline characteristics, AEs, and other safety assess-
ments were presented as descriptive statistics (continu-
ous variables) or frequency tables (categorical variables).
The intent-to-treat population, which included all 
patients randomized at baseline, was also the efficacy 
population. The safety population included all rand-
omized patients who received at least one dose or partial 
dose of study medication.
Endnote
Results from this study were presented in part at the 
Multinational Association of Supportive Care in Cancer 
International Symposium, New York, NY, June 28–30, 
2012.
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